Warneford Partners is a private pharmaceutical development and marketing business with a focus on innovative products within the gastrointestinal therapeutic area. Established as a result of an ongoing collaboration between its directors it is focused on the development of a range of naloxone based medicines for global introduction. Its first product, Nalolax® has proven in clinical trials to be highly effective in reversing opioid-induced constipation.
Frank is a pharmacist whose industry career was established in DuPont Pharmaceuticals. At DuPont he held a number of increasingly senior position in regulatory affairs, quality and manufacturing culminating in his appointment as VP Manufacturing Europe. Following the acquisition by Bristol Myers Squibb, he was appointed Managing Director of the German subsidiary.
Frank is now the co-owner of Merlin Pharmacy, a German pharmacy business specialising in oncology and compounding products.
He graduated with an MSc in Pharmacy and a PhD in Pre-Clinical Pharmacology from the Frankfurt University. He is a Post-Doctoral Fellow at the University’s Pharmacological Institute of Scientists, having previously been a Lecturer.
Simon has more than 17 years’ experience in corporate finance, having worked previously for Credit-Suisse, Morgan Stanley and UBS, among others. He has worked on an extensive range of transactions and his experience includes advising the Boards of companies such as BASF, Ciba, Novartis, DSM, Roche and Aventis, in relation to a variety of advisory assignments including mergers and acquisitions, restructurings and capital raisings.
He currently holds a number of finance and operational positions in other privately-owned pharmaceutical development & marketing businesses that he has helped establish, fund and build. He co-founded Colonis Pharma acquired by Quantum plc and Internis recently acquired by Thornton & Ross.
Simon was educated in England and France achieving a BA Hons in Economics and a Licence es Sciences Economiques, respectively.
Head of Scientific and Regulatory Affairs
Steve is a commercial pharmacist working within the speciality pharmaceutical sector for the last 30 years. His expertise lies in the development of niche medicines and practical solutions to commercialise products in areas of unmet need.
Previously Steve founded a chain of community pharmacies and subsequently built the Stevenden Healthcare Group. He also worked in product development at ICN ( Now Valeant, Womens First Healthcare and latterly BIBRA. He co-founded Colonis Pharma , acquired by Quantum plc.
Steve graduated with a BSc (Hons) and MRPharmS at Sunderland University.
Head of Business Development
Thomas is a seasoned pharmaceutical executive and deal maker. Over 20 years he held a number of increasingly senior and international roles at Akzo Nobel and Organon exiting as Senior VP for Global marketing. He was then appointed as the UK’s Chief executive of Novartis Consumer Health.
From 2009-2014 Thomas advised a number of private equity and debt funds working on financial and operational turnarounds, this lead to two very successful IPOs; 4D Pharma & Quantum Pharma plc. During this time he was also Chair of Martindale Pharma, Quantum Pharma and Colonis Pharma.
Currently he holds Chairman positions at Akcros Chemicals Holding Ltd, GT Biologics Ltd, Stan Chem International Ltd and is a Non Executive director at 4D Pharma Plc.
Thomas graduated from Nijenrode University, with a BBA in Business Administration.
Head of Medical Affairs
Chris is a very experienced pharmaceutical physician and medical advisor. His clinical experience includes obstetrics and gynaecology, general practice, rheumatology and anaesthetics.
He has held a variety of positions in industry, including Medical Director at Brocades and BIBRA International, Head of Pharmacovigilance at Crescent Pharmaceuticals, Head of Clinical Research at Schering Plough and Head of the Medical Department at Organon.
Chris runs his own consultancy business CJM Medical which co-ordinates contract clinical trials and development programmes for pharmaceutical clients in Europe and the USA.
He is also the SSA (Senior Speciality Adviser) for the Faculty of Pharmaceutical Medicine’s HMT (Higher Medical Training) programme, a member of the RITA panels (Record if In-house Training Assessment) and visiting Scientist to the London School of Pharmacy (University of London).
Chris is a member of the Medical Faculty at the University of Birmingham and holds a Bachelor of Medicine, a Bachelor of Surgery and a Diploma in Pharmaceutical Medicine. He is a Fellow of the Faculty of Pharmaceutical Medicine Fellow of the Royal Society of Medicine.